Yahoo Finance High Insider Ownership Growth Companies On SEHK In July 2024
Amidst a backdrop of global market fluctuations and deepening China-U.S. trade tensions, the Hong Kong market has shown resilience with specific sectors demonstrating robust growth potential. High insider ownership in growth companies on the SEHK signals strong confidence from those who know these companies best, which can be particularly appealing in the current uncertain economic climate.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
Name | Insider Ownership | Earnings Growth |
iDreamSky Technology Holdings (SEHK:1119) | 20.2% | 104.1% |
Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
Fenbi (SEHK:2469) | 30.6% | 43% |
Tian Tu Capital (SEHK:1973) | 34% | 70.5% |
Adicon Holdings (SEHK:9860) | 22.4% | 28.3% |
Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 73.4% |
DPC Dash (SEHK:1405) | 38.2% | 90.2% |
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 100.1% |
Beijing Airdoc Technology (SEHK:2251) | 28.7% | 83.9% |
Ocumension Therapeutics (SEHK:1477) | 23.3% | 93.7% |
We'll examine a selection from our screener results.
Meitu
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Meitu, Inc. is an investment holding company specializing in image, video, and design products that enhance industry digitalization with beauty-related solutions, operating both in the People’s Republic of China and internationally, with a market capitalization of approximately HK$10.52 billion.
Operations: The company generates revenue primarily through its Internet Business segment, which posted earnings of CN¥2.70 billion.
Insider Ownership: 36.6%
Revenue Growth Forecast: 17.7% p.a.
Meitu, a company with high insider ownership in Hong Kong, recently approved significant bylaw changes and a dividend increase at its AGM. Despite some board turnover, Meitu's financials show promise with earnings expected to grow significantly over the next three years, outpacing the local market's average. However, its revenue growth projections fall short of 20% per year and one-off items have impacted earnings quality. The stock is currently trading well below its estimated fair value.
Ocumension Therapeutics
Simply Wall St Growth Rating: ★★★★★☆
Overview: Ocumension Therapeutics operates as an ophthalmic pharmaceutical platform company in the People's Republic of China, with a market capitalization of approximately HK$4.79 billion.
Operations: The company generates revenue primarily from discovering, developing, and commercializing ophthalmic therapies, totaling CN¥246.37 million.
Insider Ownership: 23.3%
Revenue Growth Forecast: 35.2% p.a.
Ocumension Therapeutics is on track to become profitable within the next three years, with earnings growth projected at a very high rate annually. Revenue is also expected to increase significantly, surpassing broader market averages in Hong Kong. Recent developments include the acceptance of a biologic license application for OT-702 by China's CDE, marking a critical step in commercializing this promising biosimilar for various eye diseases. However, its forecasted Return on Equity remains low at 3.8%.
Meituan
Simply Wall St Growth Rating: ★★★★★☆
Overview: Meituan is a technology retail company based in the People's Republic of China, with a market capitalization of approximately HK$720.84 billion.
Operations: The company generates its revenue from various technology retail operations across China.
Insider Ownership: 11.5%
Revenue Growth Forecast: 12.8% p.a.
Meituan, a prominent player in Hong Kong's tech sector, has demonstrated strong financial performance with first-quarter sales rising to CNY 73.28 billion and net income increasing to CNY 5.37 billion. The company recently announced a substantial share repurchase program valued at US$2 billion, underscoring confidence in its future growth prospects. Despite high insider ownership, there have been no significant insider sales over the past three months, aligning leadership interests with shareholder value enhancement. However, recent board changes and corporate governance amendments suggest potential shifts in strategic direction.
Where To Now?
Navigate through the entire inventory of 53 Fast Growing SEHK Companies With High Insider Ownership here.
Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Searching for a Fresh Perspective?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include SEHK:1357 SEHK:1477 and SEHK:3690.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
